Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-15
2011-03-15
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252010, C514S456000
Reexamination Certificate
active
07906515
ABSTRACT:
The present invention relates to a method of treatment of a tumour cell which comprises administering to a subject in need of treatment an effective amount of a topoisomerase-II poison, e.g. etoposide, in combination with a bis-dioxypiperazine, e.g. dexrazoxane wherein said subject is further treated with radiation.
REFERENCES:
patent: 4963551 (1990-10-01), Palepu et al.
patent: 6265385 (2001-07-01), Jensen et al.
patent: WO 97/25044 (1977-07-01), None
patent: 97/25044 (1997-07-01), None
International Search Report of PCT/IB2005/000670, mailed Apr. 6, 2006.
Schroeder et al., “Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent”, Cancer Chemotherapy and Pharmacology, vol. 53, No. 1, Jan. 2004, pp. 91-93, XP008061658.
Schroeder et al., “Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide”, Cancer Chemotherapy and Pharmacology, vol. 52, No. 2, Aug. 2003, pp. 167-174, XP008061654.
Holm B et al., “Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide”, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, Jun. 1998, vol. 4, No. 6, Jun. 1998, pp. 1367-1373, XP002373086.
Jensen et al., “DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide”, Biochemical Pharamcology, Oct. 1, 1997, vol. 54, No. 7, pp. 755-759, XP008061671.
Holm Bente et al., “ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors”, Cancer Chemoterhapy and Pharmacology, vol. 38, No. 3, 1996, pp. 203-209, XP008061672.
Minehan Kern et al., “The interaction of etoposide with radiation: Variation in cytotoxicity with the sequence of treatment”, Life Sciences, vol. 53, No. 15, 1993, pp. 237-242, XP008061879.
Sehested et al, “Antagonistic Effect of the Cardioprotector (+)-1,2-bis(3,5-Dioxopiperazinyl-1-YL)Propane (ICRF-187) on DNA Breaks and Cytotoxicity Induced by the Topoisomerase II Directed Drugs Daunorubicin and Etoposide (VP-16)”, Biochemical Pharmacology, vol. 46, No. 3, pp. 389-393, 1993.
Hofland Kenneth
Jensen Peter Buhl
Kristjansen Paul
Sehested Maxwell
Thougaard Annemette
Jiang Shaojia Anna
Krishnan Ganapathy
Nixon & Vanderhye P.C.
Topotarget A/S
LandOfFree
Cancer treatment with topoisomerase-II inhibitor, a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancer treatment with topoisomerase-II inhibitor, a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer treatment with topoisomerase-II inhibitor, a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2760293